After over a decade spent building Incyte up into a competitive commercial drugmaker, the company’s longtime CEO Hervé Hoppenot is making his exit and passing the baton to biopharma veteran Bill Meury. Meury’s appointment, effective immediately, was a unanimous call from Incyte’s board as his skill set, leadership experience and ability to “effectively translate scientific breakthroughs into business results” stood out, Baker noted. Meury joined Incyte with a track record of dealmaking, and his appointment raised the possibility of Incyte becoming an M&A target.
Read the full article: Incyte Waves Goodbye to Longtime CEO Hervé Hoppenot as New Appointment Raises M&A Hopes //
Source: https://www.fiercepharma.com/pharma/incyte-freshens-leadership-ceo-transition-waving-goodbye-longtime-head-herve-hoppenot